**Trader sentiment on full federal marijuana rescheduling from Schedule I to III reflects the partial April 2026 action and stalled broader process.** In late April 2026, the Department of Justice issued a final rule moving FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, effective April 28, while leaving recreational and unlicensed cannabis in Schedule I. A separate DEA administrative hearing on broader rescheduling opened June 29, 2026, and concluded no later than July 15, but featured only opponents as selected participants and produced no final rule change. A September 9, 2026, D.C. Circuit ruling rejected efforts to block the partial rescheduling pending further litigation, allowing it to remain in effect. The DEA has filed briefs supporting Schedule III criteria for marijuana based on accepted medical use, yet significant procedural and legal hurdles persist. Upcoming resolution depends on the administrative law judge’s recommendation, any final DEA action, and ongoing court challenges, with no major new catalysts in the past month.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano$810,189 Wol.
Sep 30, 2026
September 30
2%
December 31
16%
$810,189 Wol.
September 30
$679 Wol.
2%
December 31
$199,939 Wol.
16%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Trader sentiment on full federal marijuana rescheduling from Schedule I to III reflects the partial April 2026 action and stalled broader process.** In late April 2026, the Department of Justice issued a final rule moving FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, effective April 28, while leaving recreational and unlicensed cannabis in Schedule I. A separate DEA administrative hearing on broader rescheduling opened June 29, 2026, and concluded no later than July 15, but featured only opponents as selected participants and produced no final rule change.
A September 9, 2026, D.C. Circuit ruling rejected efforts to block the partial rescheduling pending further litigation, allowing it to remain in effect. The DEA has filed briefs supporting Schedule III criteria for marijuana based on accepted medical use, yet significant procedural and legal hurdles persist. Upcoming resolution depends on the administrative law judge’s recommendation, any final DEA action, and ongoing court challenges, with no major new catalysts in the past month.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Rynek otwarty: Jul 31, 2026, 5:46 PM ET
Wolumen
$810,189Data zakończenia
Jan 1, 2027Rynek otwarty
Jul 31, 2026, 5:46 PM ETRozstrzygający
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Trader sentiment on full federal marijuana rescheduling from Schedule I to III reflects the partial April 2026 action and stalled broader process.** In late April 2026, the Department of Justice issued a final rule moving FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, effective April 28, while leaving recreational and unlicensed cannabis in Schedule I. A separate DEA administrative hearing on broader rescheduling opened June 29, 2026, and concluded no later than July 15, but featured only opponents as selected participants and produced no final rule change.
A September 9, 2026, D.C. Circuit ruling rejected efforts to block the partial rescheduling pending further litigation, allowing it to remain in effect. The DEA has filed briefs supporting Schedule III criteria for marijuana based on accepted medical use, yet significant procedural and legal hurdles persist. Upcoming resolution depends on the administrative law judge’s recommendation, any final DEA action, and ongoing court challenges, with no major new catalysts in the past month.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Wolumen
$810,189Data zakończenia
Jan 1, 2027Rynek otwarty
Jul 31, 2026, 5:46 PM ETRozstrzygający
0x65070BE91...**Trader sentiment on full federal marijuana rescheduling from Schedule I to III reflects the partial April 2026 action and stalled broader process.** In late April 2026, the Department of Justice issued a final rule moving FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, effective April 28, while leaving recreational and unlicensed cannabis in Schedule I. A separate DEA administrative hearing on broader rescheduling opened June 29, 2026, and concluded no later than July 15, but featured only opponents as selected participants and produced no final rule change. A September 9, 2026, D.C. Circuit ruling rejected efforts to block the partial rescheduling pending further litigation, allowing it to remain in effect. The DEA has filed briefs supporting Schedule III criteria for marijuana based on accepted medical use, yet significant procedural and legal hurdles persist. Upcoming resolution depends on the administrative law judge’s recommendation, any final DEA action, and ongoing court challenges, with no major new catalysts in the past month.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania